Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Toxicity of oral iron chelator L1.

Literature DB >> 8096974

Toxicity of oral iron chelator L1.

V Berdoukas, P Bentley, H Frost, H P Schnebli.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1993 PMID： 8096974 DOI： 10.1016/0140-6736(93)92443-w

Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

1. In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator: correlation with physico-chemical properties and oral activity.

Authors: N Lowther; R Fox; B Faller; H Nick; Y Jin; T Sergejew; Y Hirschberg; R Oberle; H Donnelly
Journal: Pharm Res Date: 1999-03 Impact factor: 4.200

2. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.

Authors: John C Wood; Maya Otto-Duessel; Ignacio Gonzalez; Michelle I Aguilar; Hiro Shimada; Hanspeter Nick; Marvin Nelson; Rex Moats
Journal: Transl Res Date: 2006-11 Impact factor: 7.012

Review 3. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.

Authors: J A Barman Balfour; R H Foster
Journal: Drugs Date: 1999-09 Impact factor: 9.546

Review 4. World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors: Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal: World J Methodol Date: 2014-09-26

Review 5. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors: G J Kontoghiorghes
Journal: Indian J Pediatr Date: 1993 Jul-Aug Impact factor: 1.967

Review 6. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors: George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal: Drug Saf Date: 2003 Impact factor: 5.606

Toxicity of oral iron chelator L1.

1. In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator: correlation with physico-chemical properties and oral activity.

2. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.

Review 3. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.

Review 4. World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Review 5. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Review 6. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

7. Iron chelators as therapeutic agents against Pneumocystis carinii.

Review 8. A risk-benefit assessment of iron-chelation therapy.

9. Clinically approved iron chelators influence zebrafish mortality, hatching morphology and cardiac function.

10. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective.